- In November 2023, Glaukos Corporation announced that the FDA approved its iStent inject Trabecular Micro-Bypass System for treating open-angle glaucoma (OAG). This minimally invasive glaucoma surgery (MIGS) device is implanted in the eye's trabecular meshwork to enhance drainage and lower intraocular pressure (IOP), providing a more effective and safer treatment option for glaucoma patients
- In October 2023, Johnson & Johnson Vision received CE Mark approval for its Xact Robotic System for glaucoma surgery. This robotic-assisted surgical platform is designed to enhance surgeon precision and control during MIGS procedures. The system aims to improve the accuracy of surgeries, offering better outcomes and fewer complications in treating glaucoma
- In September 2023, Alcon launched its new Hydrus Microstent in the U.S. market. This MIGS device helps lower intraocular pressure (IOP) by creating a bypass channel for aqueous humor drainage in the eye. The Hydrus Microstent offers a promising solution for patients suffering from glaucoma, improving drainage and minimizing surgical risks
- In August 2023, Bausch + Lomb announced that its enVista Aspire intermediate-optimized monofocal and toric intraocular lenses (IOLs) received FDA approval. These lenses are designed for use in cataract and glaucoma surgeries, providing patients with clear, continuous vision at all distances after surgery. The enVista Aspire IOLs improve visual quality and patient satisfaction
- In July 2023, Nova Eye Medical, Inc. received FDA clearance for its iClear Microstent. This MIGS device aims to reduce intraocular pressure (IOP) by creating a new drainage pathway for aqueous humor in the eye. The iClear Microstent offers a less invasive solution for glaucoma patients, reducing the risk of complications and improving treatment outcomes
